BAN0805 is an antibody against alpha-synuclein and a drug candidate for the treatment of Parkinson’s disease.
The goal is to develop a disease modifying treatment that stops or slows down disease progression. The project is based on research from Uppsala University in Sweden.
In 2016, BioArctic and AbbVie, a research-focused global biopharmaceutical company, entered into a strategic collaboration to develop and commercialize BioArctic’s portfolio of antibodies directed at pathological species of alpha-synuclein for the treatment of Parkinson’s disease and other potential indications.
In November 2018, AbbVie announced that they will exercise their option to license BioArctic’s alpha-synuclein antibody portfolio.
BAN0805 is the most advanced alpha-synuclein targeting antibody within the BioArctic portfolio and is being developed as a disease modifying treatment for Parkinson’s disease. AbbVie will progress BAN0805, now known as ABBV-0805, into clinical development with the first clinical study planned for 2019. BioArctic will continue to deliver on-going agreed activities in line with the on-going collaboration agreement.